These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

888 related items for PubMed ID: 17017818

  • 21. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.
    Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valentí M, Vieta E.
    Int J Neuropsychopharmacol; 2010 Feb; 13(1):5-14. PubMed ID: 19638254
    [Abstract] [Full Text] [Related]

  • 22. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials.
    Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE.
    J Clin Psychiatry; 2006 Apr; 67(4):509-16. PubMed ID: 16669715
    [Abstract] [Full Text] [Related]

  • 23. Second-generation antipsychotics for anxiety disorders.
    Depping AM, Komossa K, Kissling W, Leucht S.
    Cochrane Database Syst Rev; 2010 Dec 08; (12):CD008120. PubMed ID: 21154392
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial.
    Gao K, Wu R, Kemp DE, Chen J, Karberg E, Conroy C, Chan P, Ren M, Serrano MB, Ganocy SJ, Calabrese JR.
    J Clin Psychiatry; 2014 Oct 08; 75(10):1062-8. PubMed ID: 25007003
    [Abstract] [Full Text] [Related]

  • 25. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.
    Lorenz RA, Jackson CW, Saitz M.
    Pharmacotherapy; 2010 Sep 08; 30(9):942-51. PubMed ID: 20795849
    [Abstract] [Full Text] [Related]

  • 26. Atypical antipsychotics in the treatment of mood disorders.
    Jarema M.
    Curr Opin Psychiatry; 2007 Jan 08; 20(1):23-9. PubMed ID: 17143078
    [Abstract] [Full Text] [Related]

  • 27. Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders.
    Gao K, Sheehan DV, Calabrese JR.
    Expert Rev Neurother; 2009 Aug 08; 9(8):1147-58. PubMed ID: 19673604
    [Abstract] [Full Text] [Related]

  • 28. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials.
    Derry S, Moore RA.
    BMC Psychiatry; 2007 Aug 16; 7():40. PubMed ID: 17705840
    [Abstract] [Full Text] [Related]

  • 29. The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders.
    Pignon B, Tezenas du Montcel C, Carton L, Pelissolo A.
    Curr Psychiatry Rep; 2017 Nov 07; 19(12):103. PubMed ID: 29110139
    [Abstract] [Full Text] [Related]

  • 30. Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders.
    Keck PE, Strawn JR, McElroy SL.
    J Clin Psychiatry; 2006 Nov 07; 67 Suppl 1():8-15. PubMed ID: 16426111
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis.
    Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG.
    JAMA; 2011 Sep 28; 306(12):1359-69. PubMed ID: 21954480
    [Abstract] [Full Text] [Related]

  • 32. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH, Merry SN, Hetrick SE, Stasiak K.
    Cochrane Database Syst Rev; 2012 Sep 12; (9):CD008559. PubMed ID: 22972123
    [Abstract] [Full Text] [Related]

  • 33. A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use.
    Gao K, Ganocy SJ, Conroy C, Brownrigg B, Serrano MB, Calabrese JR.
    Psychopharmacology (Berl); 2017 Aug 12; 234(15):2233-2244. PubMed ID: 28536866
    [Abstract] [Full Text] [Related]

  • 34. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies.
    Weisler RH, Calabrese JR, Thase ME, Arvekvist R, Stening G, Paulsson B, Suppes T.
    J Clin Psychiatry; 2008 May 12; 69(5):769-82. PubMed ID: 18452345
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. An open-label trial of risperidone augmentation for refractory anxiety disorders.
    Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, Pollack MH.
    J Clin Psychiatry; 2006 Mar 12; 67(3):381-5. PubMed ID: 16649823
    [Abstract] [Full Text] [Related]

  • 37. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M, Krupka-Matuszczyk I.
    Hum Psychopharmacol; 2011 Jan 12; 26(1):81-5. PubMed ID: 23055416
    [Abstract] [Full Text] [Related]

  • 38. Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.
    Citrome L, Kalsekar I, Guo Z, Laubmeier K, Hebden T.
    Clin Ther; 2013 Dec 12; 35(12):1867-75. PubMed ID: 24119767
    [Abstract] [Full Text] [Related]

  • 39. Clinical highlights in bipolar depression: focus on atypical antipsychotics.
    Calabrese JR, Elhaj O, Gajwani P, Gao K.
    J Clin Psychiatry; 2005 Dec 12; 66 Suppl 5():26-33. PubMed ID: 16038599
    [Abstract] [Full Text] [Related]

  • 40. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
    Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR, BOLDER II Study Group.
    J Clin Psychopharmacol; 2006 Dec 12; 26(6):600-9. PubMed ID: 17110817
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 45.